Summary
Introduction
Inflammasomes are a suite of multi-protein complexes that play central roles in innate immune responses through their ability to recruit and activate caspase-1 (Broz and Dixit, 2016; Lamkanfi and Dixit, 2014) . This cysteine protease cleaves the cytokines interleukin (IL)-1β and IL-18 and drives pyroptosis, a highly inflammatory regulated cell death mode that is induced by cleavage of gasdermin D (GSDMD) (Kayagaki et al., 2015; Shi et al., 2015) . Amongst the different inflammasome pathways, the NLRP3 inflammasome responds to the broadest suite of inflammasome agonists that includes diverse pathogen-associated molecular patterns (PAMPs), host-derived danger-associated molecular patterns (DAMPs) like ATP, protein aggregates and β-fibrils such as β-amyloid, a broad range of environmental insults and ionophores such as nigericin and medically relevant crystals such as alum, CCPD, MSU, silica and asbestos (Broz and Dixit, 2016; Lamkanfi and Dixit, 2014) . Moreover, the NLRP3 inflammasome is engaged by Gram-negative pathogens, lipopolysaccharides (LPS) of which are sensed in the cytosol by the non-canonical NLRP3 inflammasome pathway (Hagar et al., 2013; Kayagaki et al., 2011; Kayagaki et al., 2013; Shi et al., 2014) . Through the latter mechanism, cleavage of GSDMD by caspase-11 -and its human orthologs caspases 4 and 5 -promotes assembly of cytolytic GSDMD pores in the plasma membrane that also activate the NLRP3 inflammasome to drive caspase-1-dependent IL-1β and IL-18 maturation (Kayagaki et al., 2015; Kayagaki et al., 2011) . Consistent with the chemical diversity of NLRP3 stimuli, activation of the NLRP3 inflammasome is thought to converge on sensing of a secondary messenger or cellular state that is universally induced by NLRP3-activating agents (MunozPlanillo et al., 2013) .
Aberrant NLRP3 inflammasome activity is thought to contribute to the pathogenesis of many chronic diseases, including inflammatory diseases such as gout and pseudogout, metabolic diseases like atherosclerosis and NAFLD/NASH, and neurodegenerative diseases like Alzheimer's disease, Parkinson's disease and multiple sclerosis (Mangan et al., 2018; Voet et al., 2019) . Moreover, gain-of-function mutations in and around the central NACHT domain of NLRP3 cause three autosomal dominantly inherited periodic fever syndromes that together are known as cryopyrin-associated periodic syndrome (CAPS). Symptoms span a clinical spectrum with Familial Cold Autoinflammatory Syndrome (FCAS) being the mildest; Mucklewell syndrome (MWS) being of moderate severity; and Neonatal Onset Multisystem Inflammatory Disease (NOMID)/Chronic Infantile Neurological, Cutaneous and Articular Syndrome (CINCA) being the most severe form of CAPS, featuring systemic inflammation, neurological and sensory impairment and deforming arthropathy (Van Gorp et al., 2019) .
Selective and potent inhibitors of the NLRP3 inflammasome may have broad therapeutic potential in CAPS and other diseases (Mangan et al., 2018; Voet et al., 2019) . Early studies with the sulfonylurea drug glyburide provided proof-of-concept that PAMP-, DAMP-, and crystal-induced activation of the NLRP3 inflammasome pathway may be selectively targeted without interfering with other inflammasome pathways (Lamkanfi et al., 2009 ). The related diarylsulfonylurea compound MCC950/CRID3 was originally reported as an inhibitor of IL-1ß secretion (Laliberte et al., 2003) , and subsequently shown to potently and selectively inhibit the NLRP3 inflammasome pathway in murine and human macrophages and monocytes with IC50 values in the low nM range (Coll et al., 2015; Primiano et al., 2016) . There is significant interest in the discovery and development of diarylsulfonylurea CRIDs such as MCC950/CRID3
for the treatment of CAPS and other diseases based on its ability to curb inflammatory pathology in mouse models of CAPS, the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis, NAFLD/NASH, and many other inflammatory disease models (Mangan et al., 2018; Voet et al., 2019) . However, the direct molecular target of MCC950/CRID3 in the NLRP3 inflammasome pathway has remains elusive, hampering the rational optimization and development of MCC950/CRID3-based therapies.
Utilizing two different chemoproteomic strategies, we here demonstrate that the NACHT domain of NLRP3 is the molecular target of diarylsulfonylurea CRIDs. Interestingly, we find photoaffinity labelling (PAL) of the NACHT domain of NLRP3 requires an intact (d)ATP-binding pocket and is substantially reduced for most CAPS-associated NLRP3 mutants. In accordance, NLRP3-driven inflammatory pathology in mouse models of CAPS was not efficiently curbed by MCC950/CRID3. Consistently, MCC950/CRID3 abolished circulating levels of interleukin (IL)-1β and IL-18 in LPS-challenged wildtype mice but not in CAPS mice and ex vivo-stimulated mutant macrophages. These results identify the central NACHT domain of wildtype NLRP3 as the molecular target of MCC950/CRID3 and show that CAPS-related NACHT mutations prevent efficient MCC950/CRID3 inhibition. Collectively, this work suggests that MCC950/CRID3-based therapies may effectively treat inflammation driven by wildtype NLRP3, but not CAPSassociated mutants.
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Results
MCC950/CRID3 selectively binds to human and murine NLRP3
As a first approach to identify the molecular target of MCC950/CRID3, we made use of photoaffinity labeling (PAL) in combination with click chemistry (Smith and Collins, 2015) . Guided by limited structure-activity studies, a cell-permeable photo-affinity probe was synthesized (Fig.   1A , compound PAL-CRID3) that contains a photo-reactive benzophenone group to enable direct covalent labeling of MCC950/CRID3 targets upon exposure to UV light. The alkyne functionality in PAL-CRID3 allowed in situ click reaction with a 5-carboxytetramethylrhodamine (Fig. 1b, c) . We hypothesize somewhat lesser activity of PAL-CRID3 compared to MCC950/CRID3 is a combination of physical property and binding differences that decrease target occupancy.
To screen candidate targets of MCC950/CRID3, HEK293T cells overexpressing FLAG-epitope tagged fusions of the human inflammasome sensor proteins NLRP3, NLRP1, NLRC4, NLRP6 and MEFV were incubated with PAL-CRID3 and exposed to UV light to allow covalent binding of PAL-CRID3 to potential targets. Following cell lysis, the probe was conjugated to the TAMRA reporter by click chemistry, and protein lysates were separated by SDS-PAGE. Notably, in-gel fluorescence imaging showed significant TAMRA labelling of ectopically expressed NLRP3, but not other inflammasome sensors in the panel (Fig. 1d) . To further extend these findings, we next confirmed binding to murine Nlrp3 (Fig. 1e) . As controls, protein phosphatase PP1Cb and glutathione S-transferase GSTO1, which has been proposed as the target of CRID compounds (Laliberte et al., 2003) , were not labelled by PAL-CRID3 (Fig. 1e) . Moreover, binding of PAL-CRID3 to human NLRP3 and murine Nlrp3 only was observed following UV crosslinking and labelling was rescued by competition with excess MCC950/CRID3 (Fig. 1e) , thus ruling out non-specific cross-linking and validating specificity of these findings. To further characterize the interaction 6 of PAL-CRID3 with components of the NLRP3 inflammasome, we assessed binding to human NEK7, ASC, caspase-1 and GSDMD. PAL-CRID3 failed to label the NLRP3 inflammasome components in the panel apart from NLRP3 (Fig. 1f) . Collectively, these results suggest that CRID compounds, including MCC950/CRID3, inhibit NLRP3 inflammasome signalling by directly binding to NLRP3.
To confirm and extend these findings to endogenous NLRP3, we made use of recently described iBody technology to immobilize MCC950/CRID3 on polymers that enabled immunoprecipitation of MCC950/CRID3 targets . In brief, MCC950/CRID3 was stochastically modified with a photo-activatable phenyldiazirine linker, and the resulting isomeric mixture was conjugated to a hydrophilic N-(2-hydroxypropyl)methacrylamide (HPMA) polymer backbone that is decorated with a biotin affinity tag (for details please refer to the Materials and Methods section and ). The MCC950/CRID3 iBody conjugate is further referred to as iBody U121. The corresponding iBody conjugate lacking MCC950/CRID3 served as a negative control and is referred to as iBody U126.
BMDMs of wildtype (C57BL/6J) and Nlrp3 -/-mice were primed with LPS to transcriptionally upregulate NLRP3 inflammasome components (Bauernfeind et al., 2009) , and cell lysates were subsequently incubated with iBody U121 (MCC950/CRID3) or iBody U126 (control) followed by immunoprecipitation with streptavidin-coupled beads. Contrary to control iBody U126, iBody U121 immunoprecipitated endogenous Nlrp3 from wildtype BMDMs (Fig. 1g) . iBody U121 failed to pulldown inflammasome components ASC and caspase-1 (Fig. 1g) . As expected, the immunoreactive band was absent from immunoprecipitates and lysates of LPS-primed Nlrp3-deficient macrophages (Fig. 1g) . Given the lack of suitable antibodies to detect endogenous NLRC4, we made use of reported Nlrc4 3xFlag/3xFlag knock-in mice (Matusiak et al., 2015; Qu et al., 2012) to further validate selective targeting of NLRP3. Consistent with our earlier results, only iBody U121 precipitated endogenous Nlrp3 from LPS-primed Nlrc4 3xFlag/3xFlag BMDMs (Fig. 1h) . Comparable background binding of Nek7 was observed with iBody U121 and control iBody U126, whereas neither Nlrc4 (detected using FLAG antibodies), Nek7 nor Pyrin were retrieved in iBody U121 immunoprecipates of LPS-primed Nlrc4 Flag/Flag BMDMs (Fig. 1h) . Collectively, these results show that MCC950/CRID3 selectively binds to NLRP3 in LPS-primed macrophages. MCC950/CRID3 binds, we generated deletion mutants that cover the following three regions of human NLRP3: (i) the N-terminal PYD; (ii) the central NACHT domain (comprising the NOD domain and helical domain 2 (HD2)); and (iii) the carboxy-terminal LRR region (Fig. 2a) .
Consistent with our previous results (Fig. 1) , TAMRA analysis showed significant binding of PAL-CRID3 to ectopically expressed full-length NLRP3 in HEK293T cells (Fig. 2b) . In addition, we observed binding of PAL-CRID3 to the isolated NACHT (NOD + HD2) region of NLRP3, but not to the PYD and LRR domains (Fig. 2b) . Labelling of both full-length NLRP3 and the isolated NACHT region by PAL-CRID3 was rescued by treatment with an excess amount of free MCC950/CRID3 (Fig. 2b) , confirming specificity and suggesting PAL-CRID3 and MCC950/CRID3 compete for the same binding site. Binding of ATP/dATP to the Walker A pocket in the NACHT domain is essential for NLRP3 inflammasome assembly and function (Duncan et al., 2007) .
Interestingly, mutation of the Walker A motif (GKT 229 /AAA) in full-length Nlrp3 abolished PAL-CRID3 binding (Fig. 2c) , suggesting that an intact ATP binding pocket is required for strongest binding of diarylsulfonylurea CRID compounds.
The central NACHT domain of NLRP3 also contains most reported gain-of-function mutations that cause CAPS disease (https://infevers.umai-montpellier.fr/web/index.php). This prompted us to explore PAL-CRID3 binding to CAPS-associated NLRP3 mutants. Unexpectedly, introducing a random selection of 6 different CAPS mutations in the NACHT domain of human NLRP3 that are associated with respectively MWS (NLRP3 R325W , NLRP3 R260L , NLRP3 A352V ), FCAS (NLRP3 A439V , NLRP3 L305P ) or NOMID (NLRP3 R260P ) all blunted binding of PAL-CRID3 to full-length human NLRP3 (Fig. 2d) . The classical MWS A352V and FCAS L353P mutations in human NLRP3 correspond to the A350V and L351P mutations that have been knocked into the murine Nlrp3 gene to model CAPS disease in mice (Brydges et al., 2009) . Notably, the Nlrp3 A350V mutant did not significantly affect labelling by PAL-CRID3, whereas the Nlrp3 L351P mutation abolished labelling by PAL-CRID3 (Fig. 2e) . Together, these results suggest that photoaffinity labelling of the NACHT domain requires an intact (d)ATP-binding pocket and is substantially reduced for most CAPS-associated NLRP3 mutants.
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MCC950/CRID3 inhibits the inflammasome in wildtype but not Nlrp3 L351P macrophages
Considering that our observation that CAPS-associated Nlrp3 mutants escape PAL-CRID3 binding may have potential implications for treating CAPS with MCC950/CRID3, we sought to functionally validate these results with MCC950/CRID3 in the reported Nlrp3 L351P CAPS model (Brydges et al., 2009) . To this end, mice that were homozygous for the Nlrp3 L351P allele were bred to transgenic mice that hemizygously expressed the tamoxifen-inducible Cre-ERT2 fusion gene (CreT) (Ventura et al., 2007) . Following tamoxifen treatment and excision of the floxed neomycin resistance cassette, BMDMs of the resulting Nlrp3 L351P/+ CreT + mice expressed Nlrp3 from both the wildtype and Nlrp3 L351P alleles. Macrophages from Cre-ERT2-negative littermates (Nlrp3 L351P/+ CreT -), which only express Nlrp3 from the wildtype allele, were used as controls in these experiments.
Culture media of LPS-stimulated Nlrp3 L351P/+ CreT + macrophages contained significant levels of IL-1β ( Fig. 3a) and IL-18 ( Fig. 3b ) that were associated with marked maturation of caspase-1 and IL-1β in cell lysates (Fig. 3c) . As reported (Brydges et al., 2009 ), these LPS-induced inflammasome responses were driven by the CAPS-associated Nlrp3 L351P allele because Nlrp3 L351P/+ CreT -BMDMs failed to secrete detectable levels of IL-1β ( Fig. 3a) and IL-18 ( Fig.   3b) , and did not contain mature caspase-1 and IL-1β in their cell lysates (Fig. 3c) . Consistent with our previous results that CAPS-associated Nlrp3 L351P escaped PAL-CRID3 binding, we found that MCC950/CRID3 failed to inhibit the above inflammasome responses driven by the Nlrp3 L351P allele. We confirmed that MCC950/CRID3 was active against wildtype NLRP3 because it abolished levels of LPS-ATP-induced secretion of IL-1β ( Fig. 3d) and IL-18 ( Fig. 3e) in culture media of Nlrp3 L351P/+ CreT -BMDMs (that are solely driven by wildtype Nlrp3 in this genotype given the absence of a Cre-ERT2 transgene), as well as the concomitant maturation of caspase-1 and IL-1β in the corresponding cell lysates (Fig. 3f) . Similarly, MCC950/CRID3 abolished LPS+nigericin-induced secretion of IL-1β ( Fig. 3g) and IL-18 (Fig. 3h) , and maturation of caspase-1 and IL-1β by Nlrp3 L351P/+ CreT -macrophages (Fig. 3i) . In marked contrast, LPS+ATP-and LPS+nigericin-induced inflammasome responses were insensitive to MCC950/CRID3 blockade in Nlrp3 L351P/+ CreT + BMDMs that express both the Nlrp3 L351P allele and wildtype Nlrp3 ( Fig. 3d-i) . Together, these results establish that the CAPS-associated Nlrp3 L351P allele is insensitive to MCC950/CRID3 inhibition.
MCC950/CRID3 inhibition of inflammasome responses in Nlrp3 A350V macrophages
Unlike for Nlrp3 L351P , labelling of Nlrp3 A350V by G03086997 was not significantly impacted by the mutation (Fig. 2e) . To address whether this was mirrored by potent inhibition of Nlrp3 A350V -driven inflammasome responses by MCC950/CRID3, mice that were homozygous for the previously reported Nlrp3 A350V allele were bred to the Cre-ERT2 (CreT) transgenic mice described above. Following tamoxifen treatment and excision of the floxed neomycin resistance cassette, BMDMs of the resulting Nlrp3 A350V/+ CreT + mice expressed Nlrp3 from both the wildtype and Nlrp3 A350V alleles. BMDMs from CreT-negative littermates (Nlrp3 A350V/+ CreT -), which only express Nlrp3 from the wildtype allele, were used as controls in these experiments.
Like Nlrp3 L351P/+ CreT + BMDMs (Fig. 3a-c) , Nlrp3 A350V/+ CreT + macrophages that expressed Nlrp3 A350V secreted high levels of secreted IL-1β ( Fig. 4a) and IL-18 (Fig. 4b ) in response to LPS stimulation alone. This was accompanied by proteolytic maturation of caspase-1 and proIL-1β as demonstrated by immunoblot analysis (Fig. 4c) . As expected, these responses were absent from LPS-stimulated Nlrp3 A350V/+ CreT -BMDMs that expressed wildtype Nlrp3 only (Fig. 4a-c) . Fig. 4a) and IL-18 (Fig. 4b) secretion, and Nlrp3 A350V -driven cleavage of caspase-1 and IL-1β (Fig. 4c) in marked contrast to Nlrp3 L351P/+ CreT + macrophages that proved insensitive to MCC950/CRID3 blockade ( Fig. 3a-c) .
MCC950/CRID3 potently inhibited LPS-induced IL-1β (
LPS+ATP and LPS+nigericin potently triggered IL-1β and IL-18 secretion, and maturation of caspase-1 and proIL-1β from both Nlrp3 A350V/+ CreT + and Nlrp3 A350V/+ CreT -control BMDMs ( Fig.   4d-i) . However, whereas MCC950/CRID3 abolished LPS+ATP-and LPS+nigericin-induced IL-1β secretion from Nlrp3 A350V/+ CreT -control BMDMs, it failed to alter secretion of IL-1β from parallelly-treated Nlrp3 A350V/+ CreT + BMDMs (Fig. 4d, g ). MCC950/CRID3 also abrogated LPS+ATP-and LPS+nigericin-induced IL-18 secretion from control Nlrp3 A350V/+ CreT -BMDMs, but only reduced IL-18 secretion from parallelly stimulated Nlrp3 A350V/+ CreT + macrophages by about 50% (Fig. 4e, h ). Aligned with these results, MCC950/CRID3 inhibited LPS+ATP-and LPS+nigericin-induced cleavage of caspase-1 and proIL-1β in control Nlrp3 A350V/+ CreT -BMDMs but not in Nlrp3 A350V/+ CreT + macrophages (Fig. 4f, i) . Together, these results show that although binding of PAL-CRID3 to Nlrp3 A350V was not significantly compromised, the mutation subtly alters the ability of MCC950/CRID3 to inhibit inflammasome activation in primary 10 macrophages, with potent inhibition seen only in response to LPS but not following 'signal 2' triggers such as ATP and nigericin.
Inflammasome inhibition in homozygous mutant macrophages
The studies described above were performed in heterozygous macrophages that express both wildtype and CAPS-associated Nlrp3 mutants. Considering that the Nlrp3 NACHT region facilitates Nlrp3 oligomerization, we decided to further assess MCC950/CRID3 responses in macrophages that uniquely express the CAPS-associated Nlrp3 mutants in the absence of wildtype Nlrp3. To do so, we transduced wildtype, Nlrp3 A350V/A350V and Nlrp3 L351P/L351P BMDMs with Cre recombinase-expressing lentiviruses to excise the neomycin resistance cassette that is placed upstream of the Nlrp3 mutation and allow expression of the CAPS-associated Nlrp3 mutants.
As expected, wildtype macrophages failed to secrete IL-1β and IL-18 in response to LPS alone, and MCC950/CRID3 abolished secretion of IL-1β and IL-18 when wildtype BMDM were stimulated with LPS+ATP or LPS+nigericin (Fig. 5a, b) . LPS stimulation alone was sufficient to induce extracellular release of IL-1β and IL-18 in homozygous Nlrp3 L351P/ L351P and Nlrp3 A350V/ A350V macrophages ( Fig. 5c-f) . MCC950/CRID3 inhibited Nlrp3 L351P -induced secretion of IL-1β and IL-18 neither in response to LPS alone, nor when combined with 'signal 2' agents ATP or nigericin (Fig. 5c, d) , unequivocally establishing that Nlrp3 L351P -induced inflammasome activation is insensitive to MCC950/CRID3 blockade. Consistent with our previous results in heterozygous Nlrp3 A350V mutant macrophages, MCC950/CRID3 partially inhibited LPS-induced IL-1β and IL-18 levels in culture supernatants of homozygous Nlrp3 A350V/ A350V macrophages, but this was not observed in response to LPS+ATP and LPS+nigericin (Fig. 5e, f) .
In vivo MCC950/CRID3 inhibition of inflammasome activation in CAPS disease models
Myeloid-specific expression of the Nlrp3 L351P and Nlrp3 A350V alleles in knock-in mice was shown to drive systemic inflammation accompanied by respectively embryonic and perinatal lethality that in both cases required Nlrp3 inflammasome activation (Brydges et al., 2009) . To seek further validation of the notion that the Nlrp3 L351P mutations escapes MCC950/CRID3 inhibition, we next investigated how MCC950/CRID3 treatment impacts on the CAPS phenotype of Nlrp3 L351P/+ CreT + mice. As expected, serum levels of IL-1β, IL-18 and IL-6 were significantly increased in Nlrp3 L351P/+ CreT + mice three days after tamoxifen dosing relative to 11 the basal levels of tamoxifen-treated Nlrp3 L351P/+ CreT -littermate mice (Supplementary Fig. 1a-c) . Moreover, tamoxifen treatment resulted in Nlrp3 L351P/+ CreT + mice presenting with substantial weight loss and mortality, with all mice being lost or requiring termination because of humane endpoints within 5 days after commencing tamoxifen treatment (Fig. 6a, b) . As a control, tamoxifen administration did not alter body weight or survival of Nlrp3 L351P/+ CreTmice (Fig. 6a, b) . Daily i.p. injection of MCC950/CRID3 did not rescue body weight loss or mortality rates of Nlrp3 L351P/+ CreT + mice, suggesting that MCC950/CRID3 failed to inhibit in vivo Nlrp3 L351P -induced inflammasome activation (Fig. 6a, b) . In agreement, i.p. dosing of MCC950/CRID3 failed to reduce tamoxifen-induced levels of IL-1β, IL-18 and IL-6 in serum of Nlrp3 L351P/+ CreT + mice (Fig. 6c-e) . Thus, the CAPS-associated L351P mutation renders Nlrp3 insensitive to MCC950/CRID3 inhibition.
Our results in Nlrp3 A350V macrophages showed that this mutation subtly altered the ability of MCC950/CRID3 to inhibit inflammasome activation with potent inhibition seen only in response to LPS but not following 'signal 2' triggers such as ATP and nigericin (Fig. 4) . To determine how this translates to the in vivo disease setting, we analyzed circulating cytokine levels and body weight loss of Nlrp3 A350V/+ CreT + mice following tamoxifen administration.
Although there was a trend towards increased serum levels of IL-1β, the low measured concentrations did not reach statistical significance compared to tamoxifen-treated Nlrp3 A350V/+ CreT -littermate mice (Supplementary Fig. 1d ). However, serum concentrations of IL-18 and IL-6 were signficantly elevated in tamoxifen-treated Nlrp3 A350V/+ CreT + mice relative to Nlrp3 A350V/+ CreT -littermates (Supplementary Fig. 1e, f) . Nevertheless, levels of the latter cytokines were on average 10 to 20-fold lower than seen in tamoxifen-treated Nlrp3 L351P/+ CreT + mice, a finding that is consistent with the milder pathology and the lack of mortality associated with the Nlrp3 A350V/+ CreT + CAPS model. Consistent with published findings (McGeough et al., 2012) , Nlrp3 A350V/+ CreT + mice developed an inflammatory phenotype characterized by a steady weight loss of up to 20 % within 27 days (Fig. 6e) .
Notably, daily i.p. dosing of MCC950/CRID3 stabilized Nlrp3 A350V -mediated body weight loss in Nlrp3 A350V/+ CreT + mice relative to PBS-treated controls, although differences were small and MCC950/CRID3-treated mice failed to thrive and gain weight like the Nlrp3 A350V/+ CreT -control group (Fig. 6e) . In agreement, MCC950/CRID3 had a mild or no effect on circulating levels of the systemic inflammatory markers IL-18 (Fig. 6f) and IL-6 (Fig. 6g) , respectively. Together, 12 these results establish that MCC950/CRID3 has a weak, but measurable effect on Nlrp3 A350V -induced inflammasomopathy in adult mice.
MCC950/CRID3 inhibition of LPS-induced cytokines in CAPS mutant mice
To complement the chronic CAPS disease models described above, we next evaluated the potency of MCC950/CRID3 in inhibiting acute Nlrp3-dependent inflammasome responses by subjecting wildtype and CAPS mutant mice to LPS-induced endotoxemia and probing the effect of MCC950/CRID3 on well-documented Nlrp3-dependent readouts such as LPS-induced elevation of serum levels of IL-1β and IL-18 (He et al., 2013) .
As expected, Nlrp3 L351P/+ CreT -control mice presented with increased serum levels of IL-1β and IL-18 3 hours after LPS challenge (Fig. 7a, b) . MCC950/CRID3 substantially curbed circulating IL-1β and IL-18 levels in this control group (Fig. 7a, b) , consistent with reported findings in LPSchallenged C57BL/6 mice (Coll et al., 2015) . Contrastingly, serum levels of IL-1β and IL-18 in LPS-dosed Nlrp3 L351P/+ CreT + mice were not significantly impacted by MCC950/CRID3 relative to PBS-treated Nlrp3 L351P/+ CreT + littermates (Fig. 7c, d ).
LPS challenge increased serum concentrations of IL-1β and IL-18 in Nlrp3 A350V/+ CreT -control mice, which were inhibited by MCC950/CRID3 (Fig. 7e, f) similarly to its effect on LPS-treated Nlrp3 L351P/+ CreT -control mice (Fig. 7a, b) . This is not unexpected since both genotypes express solely wildtype Nlrp3 in the absence of Cre-recombinase-mediated excision of the neomycin resistance cassette that disrupts expression of the respective CAPS-associated Nlrp3 mutants.
However, in marked contrast to Nlrp3 L351P -expressing CreT + mice (Fig. 7c, d ), MCC950/CRID3 markedly curbed circulating concentrations of IL-1β and IL-18 in Nlrp3 A350V -expressing CreT + mice (Fig. 7g, h) . These results confirm that MCC950/CRID3 potently inhibits inflammasome activation by wildtype Nlrp3 and the MWS-associated Nlrp3 A350V mutant, but not the FCASassociated Nlrp3 L351P mutant.
13
Discussion
Activation of the NLRP3 inflammasome has been observed in many diseases, and its central role in driving pathological inflammation renders it an attractive target for therapeutic intervention (Mangan et al., 2018) . Gain-of-function mutations in NLRP3 cause hereditary periodic fever syndromes that are collectively referred to as CAPS, and these patients are currently treated with biologics that target secreted IL-1 (Van Gorp et al., 2019). As reported (Ridker et al., 2017) , chronic IL-1-blockade increases risk for fatal infections and sepsis, suggesting that selective targeting of the NLRP3 inflammasome may potentially be a safer and more efficacious therapeutic strategy as it would block production of the central inflammatory mechanisms that contribute to inflammatory pathology while at the same time keeping nontargeted inflammasomes available to produce IL-1β to cope with infections.
Early studies with the sulfonylurea compound glyburide provided proof-of-concept that small molecules may selectively inhibit the NLRP3 inflammasome pathway without interfering with other inflammasomes (Lamkanfi et al., 2009 ). Subsequently, several additional compounds have been reported to specifically inhibit the NLRP3 inflammasome pathway, but the majority of these agents has weak activity against the NLRP3 inflammasome pathway (μM IC50 concentrations) and may target NF-κB signaling and other immune pathways (reviewed in (Mangan et al., 2018) ). MCC950/CRID3 is structurally related to glyburide (Coll et al., 2015; Laliberte et al., 2003) and is considered the most potent and selective inhibitor of NLRP3 inflammasome signaling reported to date. There is substantial interest in developing this chemical scaffold for the treatment of CAPS and other diseases. However, these efforts are constrained by the lack on insight in the molecular target and mechanism by which MCC950/CRID3 and related sulfonylurea molecules inhibit activation of the NLRP3 inflammasome pathway.
Making use of photoaffinity labeling and iBody technology as complementary chemical biology approaches, we here identified NLRP3 as the physical target of MCC950/CRID3. We further mapped the binding pocket to the central NACHT domain of NLRP3 and showed that photoaffinity labelling required an intact ATP/dATP binding pocket. This suggests that binding may occur at the nucleotide-binding pocket of NLRP3, although it cannot be excluded that mutations in the Walker A motif may cause long-distance conformational changes that distort a remote MCC950/CRID3 binding pocket elsewhere in the NACHT domain. Notable in this regard is our observation that a randomly selected panel of 6 CAPS-associated gain-of-14 function mutations in human NLRP3 all failed to be labelled by our PAL probe, further supporting the notion that the sulfonylurea CRID binding pocket is highly sensitive for conformational changes in the protein that are imposed by mutations. Further insight in the conformational requirements and the molecular mechanism by which MCC950/CRID3 inhibits NLRP3 activation awaits a high-resolution structural analysis of the MCC950/CRID3 binding pocket.
Considering the potential implications of these findings for treating CAPS with MCC950/CRID3-based therapies, we evaluated the functional impact of MCC950/CRID3 in two reported CAPS models (Brydges et al., 2009) . When knocked into the murine Nlrp3 sequence, the FCASassociated Nlrp3 L351P mutant (corresponding to human L353P) also failed to bind to PAL-CRID3.
Consistent with these results, our analysis of both ex vivo-stimulated mutant macrophages and in vivo CAPS and endotoxemia models unequivocally established that MCC950/CRID3 potently inhibits inflammasome activation by wildtype Nlrp3, but not the FCAS-associated Nlrp3 L351P mutant. Surprisingly, however, we found that labelling by PAL-CRID3 to the MWSlinked Nlrp3 A350V mutant (corresponding to adjacent residue A352V in human NLRP3) was not significantly impacted by the mutation. MCC950/CRID3 partially inhibited LPS-induced IL-1β and IL-18 secretion from macrophages that homozygously or heterozygously expressed the Nlrp3 A350V mutant, but inhibition of the Nlrp3 A350V inflammasome was completely lost in response to 'signal 2' agents ATP and nigericin. Consequently, MCC950/CRID3 significantly lowered IL-1β and IL-18 levels in serum of LPS-challenged Nlrp3 A350V knock-in mice, whereas it provided only limited protection against chronic CAPS mutation-driven body weight loss. The CreERT2 recombinase expression system used with our CAPS disease models allows for controlled ubiquitious tissue expression of the mutant Nlrp3 knock-in allele upon tamoxifen treatment in adult animals. Expression of the Nlrp3 A350V allele does not induce lethality in adult mice under these conditions. However, another study (Coll et al., 2015) that relied on Lysosome M-Cre-driven expression of the Nlrp3 A350V allele in cells of the myeloid lineage observed that MCC950/CRID3 rescued neonatal lethality, consistent with our observation that the Nlrp3 A350V mutant retained sensitivity to MCC950/CRID3 inhibition. This report also suggested MCC950/CRID3 inhibits LPS-induced IL-1β processing in peripheral blood mononuclear cells (PBMCs) from MWS patients. Another study showed that unlike samples from healthy controls, LPS-and LPS+ATP-induced IL-1β secretion from whole blood samples of genetically defined CAPS patients resisted MCC950/CRID3 inhibition (Grinstein et al., 2018), 15 which is consistent with our results suggesting that MCC950/CRID3-based therapies may effectively treat inflammation driven by wildtype NLRP3, but may be less effective in CAPS patients. To conclude, by identifying the molecular target of MCC950/CRID3 in the NLRP3 inflammasome pathway, and by evaluating its ability to inhibit CAPS mutatant variants, the findings presented here provide a mechanistic framework for advancing therapeutic development of this chemical scaffold and for understanding its therapeutic potential in patients. Synthesis of iBody conjugates. Experimental procedures for the preparation of the iBody conjugates have been described by and details for the production of MCC950/CRID3 iBody conjugates are provided in the Supplementary Data section.
Material and methods
Synthesis
iMac and BMDM culture. Bone marrow cells from C57BL/6 mice were immortalized by ERHoxb8 (iMac) as described previously (Wang et al., 2006) . Primary bone marrow or iMac progenitor cells were differentiated in DMEM or IMDM supplemented with 10% endotoxinfree heat-inactivated fetal bovine serum, 20-30% L929-conditioned medium, 100 U ml -1 penicillin, and 100 mg ml -1 streptomycin for 5-6 days at 37°C in a humidified atmosphere containing 5% CO2. 6 days later, cells were collected and seeded at a density of 8. Photo-labeling. Transfected HEK293T were incubated with DMSO or photo probe PAL-CRID3
(1 μM) for 30 min at 37°C in 500 μL OPTI-MEM. For competition experiments with free 17 MCC950/CRID3, 10 μM MCC950/CRID3 was added 30 min prior. Photo-labeling and click chemistry experiments were performed as described with slight modification (Mackinnon and Taunton, 2009) . Briefly, cells were washed once with ice-cold PBS and UV irradiated at 365 nm (100 W) on ice for 10 min. Cells were washed once with ice-cold PBS and frozen at -80°C. Lysis buffer was added (40 mM HEPES, 140 mM NaCl, 0.1% Triton-X-100, Roche EDTA-free complete protease inhibitor) and cells were detached with a cell scraper. Crude lysates were clarified by centrifugation (30 min at 14,000 rpm, 4°C). For click chemistry, lysates (20 μL) were incubated with 5 μL freshly mixed click cocktail comprised of: 1.7 mM TBTA in 1:4 DMSO/t-BuOH (1.5 μL); 5 mM TAMRA-N3 (0.3 μL); 50 mM TCEP (0.5 μL, freshly prepared); 10 % SDS (2.7 μL). Then, 50 mM CuSO4 (0.5 μL), was added and reactions were incubated for 1 hr at RT with gentle mixing. Reactions were quenched with 4X LDS buffer and separated by SDS-PAGE. Gels were scanned for TAMRA fluorescence on a Typhoon Trio scanner (GE Life Sciences). (Mariathasan et al., 2006) , NLRC4 3xFlag (Qu et al., 2012) were described. The CAPS models Nlrp3 A350VneoR and Nlrp3 L351PneoR (Brydges et al., 2009) Statistical analysis. GraphPad Prism 5.0 software was used for data analysis. For survival studies, data were compared by log rank (Mantel-Cox) test. Two-way ANOVA test were used to assess body weight differences between groups. Unpaired 2-tailed Student's t-test was applied to compare cytokine serum levels. Data are shown as mean with standard deviation. P < 0.05 was considered to indicate statistical significance. 
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